HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells (Q28473274)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells	scientific article

Statements

instance of

scholarly article

0 references

title

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells (English)

0 references

main subject

breast cancer

1 reference

based on heuristic

inferred from title

author

Banafshé Larijani

object named as

Banafshé Larijani

series ordinal

6

0 references

Peter Joseph Jacques Parker

object named as

Peter J Parker

series ordinal

5

0 references

Adrian Harris

object named as

Adrian Harris

series ordinal

4

0 references

author name string

Anthony Kong

series ordinal

1

0 references

Véronique Calleja

series ordinal

2

0 references

Pierre Leboucher

series ordinal

3

0 references

language of work or name

English

0 references

publication date

6 August 2008

0 references

published in

PLOS One

0 references

volume

3

0 references

issue

8

0 references

page(s)

e2881

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

6 August 2008

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

ErbB-4: mechanism of action and biology

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

Untangling the ErbB signalling network

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

19 March 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

7 April 2017

EGF-ERBB signalling: towards the systems level

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

7 April 2017

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

7 April 2017

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

7 April 2017

HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Targeting the function of the HER2 oncogene in human cancer therapeutics

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

The epidermal growth factor receptor family

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Targeting ErbB receptor signaling: a pan-ErbB approach to cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Epidermal growth factor receptor dependence in human tumors: more than just expression?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

29 September 2017

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

2 June 2018

Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

2 June 2018

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Heregulin-dependent Trafficking and Cleavage of ErbB-4

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0002881

retrieved

21 January 2018

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

27 November 2018

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2483931

retrieved

27 November 2018

EGF regulation of PITP dynamics is blocked by inhibitors of phospholipase C and of the Ras-MAP kinase pathway

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18682844

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18682844

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18682844

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1371/JOURNAL.PONE.0002881

0 references

ADS bibcode

2008PLoSO...3.2881K

0 references

PMC publication ID

2483931

0 references

PubMed publication ID

18682844

0 references

ResearchGate publication ID

23151824

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28473274&oldid=1966927619"